INS and amyloidosis: Insulin fibrillation can cause significant complications in diabetes therapy, either directly due to injection site amyloidosis (Nilsson 2016; Dische et al. 1988; Albert et al. 2007; Yumlu et al. 2009), or indirectly by decreasing the long-term stability of insulin formulations (Frokjaer and Otzen 2005; Brange and Langkjoer 1993).